You are here: Home » 0 » » Archives for 0st

INVNT Continues Commitment To EMEA-Based Clients with New Executive Creative Director

LONDON, UK, Jan. 05, 2021 (GLOBE NEWSWIRE) — INVNT. The global live brand storytelling agency today announces the appointment of Neil Mason to the role of Executive Creative Director, EMEA. Mason brings more than 20 years' experience to the role, over which he has led the creative output of experiential and integrated campaigns for brands including Nike, McLaren, Samsung, Google and Cisco.

Based in London, Mason joins from Identity Group where he was Executive Creative Director, and has held senior creative positions at agencies including George P. Johnson and Jack Morton Worldwide. Throughout the course of his career, he has managed and grown creative departments, elevated existing projects to achieve strategic business goals, and won new business across all sectors.

A judge of the internationally recognised D&AD Awards since 2018, guest lecturer at the Royal College of Art in London, and member of the board of governors at Ravensbourne University, Mason is not only passionate about his craft, but about educating and inspiring the next generation of creative talent.

Mason will report into Stephenson, and his first day is 5 January 2021.

Commenting on the appointment, Kristina McCoobery, CEO, INVNT said: “Our growth strategy has always been aligned with the ever–evolving needs of our clients, and the decision to expand INVNT's EMEA footprint is a direct result of the increased demand for our services here. Being a creative and strategic–led business, we recognised the need to recruit a leading creative for the region, so that we could continue to support clients in not just achieving but exceeding their campaign goals.”

Stephenson explained: “It was important we find an out–of–the–box thinking individual who embodies INVNT's challenger mentality in both their portfolio of work and ethos, and without a doubt, Neil ticks these boxes. An ideas guy through and through, at INVNT Neil will lean on his proven experience to devise unique concepts for virtual, hybrid and in–person experiences, across all mediums. While EMEA focused and based, he will also collaborate with our wider creative team on global campaigns which are localised in region. We're thrilled to have Neil spearheading the creative team!”

Mason added: “INVNT employees describe themselves as "wicked smart teenagers,' and I can see why. I've been blown away by the agency's ability to challenge themselves and their clients to push the boundaries and deliver great work at a time when in–person experiences haven't been possible. I'm honoured to now call myself a "wicked smart teenager'! I look forward to collaborating with the team and our clients to create experiences so unique and relevant, they cause brand messages to strike, stick and spread amongst their audiences, even at a time when the world around us is changing so rapidly.”

###

About INVNT
Founded in 2008 by Scott Cullather and Kristina McCoobery, INVNT uses the craft of live brand storytelling to create and produce live experiences that excite and unite physical and virtual audiences, globally. The company's "challenge everything' positioning statement helps clients including General Motors, Grant Thornton, Merck, PepsiCo and Samsung share their stories with every audience that matters. Part of [INVNT GROUP], THE GLOBAL BRANDSTORY PROJECT, INVNT's offices are strategically located in New York, London, Sydney, Detroit, San Francisco, Washington D.C., Stockholm and Singapore. For more information visit www.invnt.com

Attachment


GLOBENEWSWIRE (Distribution ID 8120675)

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

PRESS RELEASE

First US patient implanted in the DREAM pivotal IDE study, with the Genio system for the treatment of Obstructive Sleep Apnea (OSA)
DREAM is a pivotal, Investigational Device Exemption (IDE) study, designed to support marketing authorization in the United States

Mont–Saint–Guibert, Belgium "" 5th January 2021 "" Nyxoah S.A. (EBR: NYXH) ("Nyxoah" or the "Company"), a health–technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the successful implantation of the first US patient in the DREAM pivotal IDE study. The implantation took place at the Nose and Sinus Institute Boca Raton, Florida and was performed by Dr. Melyssa Hancock, Otolaryngology–Head & Neck surgeon.

The DREAM (Dual–sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption (IDE) trial designed to support the marketing authorization of the Genio system in the United States. This multicenter, prospective, open–label, observational study will enroll 134 patients, who will undergo the implantation procedure in up to 26 centers worldwide including sites in the United States, Germany, Belgium and Australia.

Dr. Melyssa Hancock, implanting surgeon from the Nose and Sinus Institute Boca Raton commented: " We are very excited to be chosen as the first center in the United States to implant the Genio system in a patient for treatment of obstructive sleep apnea. The teaming of the Nose and Sinus Institute of Boca Raton with the innovators at Nyxoah represents the collaboration of some of the most experienced surgeons in the United States today treating nose and airway issues with a team of brilliant international engineers. During this time of COVID–19 and virtual adaptation to everything we do, the fact that we were able to communicate in real–time during the procedure with other surgeons globally who have extensive experience with this device made it a truly extraordinary and successful endeavor."

Olivier Taelman, Chief Executive Officer of Nyxoah, added: "I'm really proud of Nyxoah's team reaching another key milestone despite all challenges due to the Covid–19 pandemic and would like to congratulate Dr. Hancock and her team for implanting the first US patient with the Genio system. Enabling US physicians to build their experience with the Genio system, combined with the existing expertise of other international surgeons participating in the DREAM study, is supporting Nyxoah's timeline for the pivotal IDE study enrollment closing by the end of Q2 2021.

– ENDS –

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.
For more information, please visit www.nyxoah.com.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen–Year Follow–up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071""1078.


GLOBENEWSWIRE (Distribution ID 1000449009)